Adagene Announces First Patient Dosed in Phase 1 Trial of Muzastotug Combination for Colorectal Cancer

• Adagene dosed the first patient in a Phase 1 trial testing muzastotug with Incyte’s INCA33890 for microsatellite stable colorectal cancer.
• The open-label dose-escalation and expansion study targets third-line patients with or without liver metastases whose disease progressed on prior therapies.
• The trial will assess whether combining the masked anti-CTLA-4 therapy with the TGFβR2 × PD-1 bispecific antibody improves responses with acceptable safety.
• Under the collaboration announced in April 2026, Incyte sponsors and conducts the study; Adagene supplies muzastotug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280700PRIMZONEFULLFEED9851867) on October 28, 2026, and is solely responsible for the information contained therein.